Floatz logo
Floatz Rating
CCC54/100
Confidence
Indicative
v0.2
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07353437CT.gov
Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)
—Not Yet Recruiting———
NCT06612814CT.gov
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
—Active Not Recruiting———
NCT06561022CT.gov
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
—Not Yet Recruiting———
NCT06254066CT.gov
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
—Not Yet Recruiting———
NCT05891093CT.gov
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
—Recruiting———
NCT05759546CT.gov
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
—Recruiting———
NCT05594095CT.gov
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
—Recruiting———
NCT05582499CT.gov
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
—Recruiting———
NCT05576389CT.gov
Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer
—Enrolling By Invitation———
NCT05085626CT.gov
Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
—Unknown———
Show 1 more trial
NCT04355858CT.gov
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
—Unknown———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Breast Cancer

AssetSponsorPhaseRating
Fluzoparib (this asset)Fudan UniversityP3CCC · 54
DarolutamideVandana AbramsonP2BBB
PertuzumabSWOG Cancer Research NetworkP4BB
PalbociclibHoffmann-La RocheP4BB
Trastuzumab DuocarmazineByondis B.V.P3BB
GoserelinTerSera Therapeutics LLCP4BB
RibociclibNational Cancer Institute (NCI)P4BB
OxaliplatinBeijing Biostar Pharmaceuticals Co., Ltd.P4BB
Eribulin MonomethanesulfonateHenan Cancer HospitalP4BB

+42 more in the Breast Cancer cohort

Other indications for Fluzoparib

IndicationSponsorPhaseRating
Primary Peritoneal Carcinoma—P3B · 62
Malignant Pancreatic Neoplasm—P3B · 62
Breast Carcinoma—P3B · 60

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Fluzoparib in Breast Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/fluzoparib-breast-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →